首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

1448720

全球增殖性糖尿病視網膜病變市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Proliferative Diabetic Retinopathy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年02月01日 | 出版商:

Value Market Research | 英文 294 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2032 年，全球增殖性糖尿病視網膜病變市場的市場規模將從 2023 年的 63.3 億美元達到近 156.9 億美元，2024-2032 年研究期間的CAGR為 10.62%。

增殖性糖尿病視網膜病變 (PDR) 是糖尿病視網膜病變的晚期和嚴重階段，糖尿病患者可能會出現這種眼睛疾病。糖尿病視網膜病變是一種與糖尿病相關的併發症，會影響視網膜血管（眼睛後部的感光組織）。 PDR 的特徵是視網膜中異常血管的生長（新生血管）。

市場動態

增殖性糖尿病視網膜病變 (PDR) 市場由多種因素驅動，主要受到全球糖尿病（尤其是第 2 型糖尿病）盛行率不斷上升的影響。人口老化的加劇進一步增加了長期糖尿病的風險，導致糖尿病性視網膜病變進展至增殖期的發生率更高。醫療保健專業人員和患者意識的提高，加上視網膜成像技術的進步，有助於早期發現和有針對性的治療。治療方法的持續創新，包括藥物干預，有助於不斷發展的 PDR 管理格局。醫療保健服務取得的改善、政府舉措以及醫療保健組織和研究機構之間的合作進一步增強了對 PDR 的整體回應。病患教育和賦權在促進定期眼科篩檢和糖尿病管理方面發揮關鍵作用，這對於早期介入至關重要。全球認知到糖尿病視網膜病變是一個重大的健康問題，加上經濟發展和醫療基礎設施的改善，共同製定了一項全面的策略來應對與增殖性糖尿病視網膜病變相關的挑戰，旨在減少視力損傷並提高患者的治療效果。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球增殖性糖尿病視網膜病變市場的各個細分市場進行了包容性評估。增殖性糖尿病視網膜病變產業的成長和趨勢為本研究提供了整體方法。

市場區隔

增殖性糖尿病視網膜病變市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人口統計數據以及即將到來的機會。

按藥物類別

抗VEGF藥物
皮質類固醇

按管理方式

可注射
口服
其他

按配銷通路

醫院藥房
零售藥局
網路藥局

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的增殖性糖尿病視網膜病變市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。增殖性糖尿病視網膜病變市場的主要參與者包括基因泰克公司、諾華公司、再生元製藥公司、輝瑞公司、默克公司、西普拉公司、艾伯維公司、博士健康公司、參天製藥公司、有限公司、Alimera Sciences、Intas Pharmaceuticals Ltd。本部分包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布，以及其他進展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：增殖型糖尿病視網膜病變公司的競爭格局

增殖性糖尿病視網膜病變市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

公司股份分析
市場集中度
Genentech Inc.

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Regeneron Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Merck KGaA

公司簡介
公司收入
產品
最近的發展

Cipla Inc.

公司簡介
公司收入
產品
最近的發展

AbbVie Inc.

公司簡介
公司收入
產品
最近的發展

Bausch Health Companies Inc.

公司簡介
公司收入
產品
最近的發展

Santen Pharmaceutical Co. Ltd.

公司簡介
公司收入
產品
最近的發展

Alimera Sciences

公司簡介
公司收入
產品
最近的發展

Intas Pharmaceuticals Ltd.

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112113620

The global demand for Proliferative Diabetic Retinopathy Market is presumed to reach the market size of nearly USD 15.69 Billion by 2032 from USD 6.33 Billion in 2023 with a CAGR of 10.62% under the study period 2024 - 2032.

Proliferative diabetic retinopathy (PDR) is an advanced and serious stage of diabetic retinopathy, an eye condition that can occur in individuals with diabetes. Diabetic retinopathy is a diabetes-related complication that affects the retinal blood vessels, the light-sensitive tissue at the back of the eye. PDR is characterized by the growth of abnormal blood vessels (neovascularization) in the retina.

MARKET DYNAMICS

The Proliferative diabetic retinopathy (PDR) market is driven by several factors, primarily influenced by the increasing global prevalence of diabetes, particularly type 2 diabetes. A growing aging population further raises the risk of prolonged diabetes, leading to a higher incidence of diabetic retinopathy progressing to the proliferative stage. Increased awareness among healthcare professionals and patients, coupled with technological advancements in retinal imaging, facilitates early detection and targeted treatment. Ongoing innovations in treatment approaches, including pharmacological interventions, contribute to the evolving landscape of PDR management. Improved access to healthcare services, government initiatives, and collaborations among healthcare organizations and research institutions further enhance the overall response to PDR. Patient education and empowerment play pivotal roles in promoting regular eye screenings and diabetes management, which is crucial for early intervention. The global recognition of diabetic retinopathy as a significant health concern, coupled with economic development and healthcare infrastructure improvements, collectively shapes a comprehensive strategy to address the challenges associated with proliferative diabetic retinopathy, aiming to reduce vision impairment and enhance patient outcomes.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of proliferative diabetic retinopathy. The growth and trends of proliferative diabetic retinopathy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the proliferative diabetic retinopathy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Anti-VEGF Agents
Corticosteroids

By Mode Of Administration

Injectable
Oral
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Proliferative Diabetic Retinopathy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Proliferative Diabetic Retinopathy market include Genentech, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., Merck KGaA, Cipla Inc., AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Alimera Sciences, Intas Pharmaceuticals Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PROLIFERATIVE DIABETIC RETINOPATHY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Mode of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Anti-VEGF Agents Historic and Forecast Sales by Regions
5.5 Corticosteroids Historic and Forecast Sales by Regions

6 . GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET ANALYSIS BY MODE OF ADMINISTRATION

6.1 Overview by Mode of Administration
6.2 Historical and Forecast Data
6.3 Analysis by Mode of Administration
6.4 Injectable Historic and Forecast Sales by Regions
6.5 Oral Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1 Overview by Distribution Channel
7.2 Historical and Forecast Data
7.3 Analysis by Distribution Channel
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE PROLIFERATIVE DIABETIC RETINOPATHY COMPANIES

9.1. Proliferative Diabetic Retinopathy Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF PROLIFERATIVE DIABETIC RETINOPATHY INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Genentech Inc.
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Novartis AG
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Regeneron Pharmaceuticals Inc.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Pfizer Inc.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Merck KGaA
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Cipla Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. AbbVie Inc.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Bausch Health Companies Inc.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Santen Pharmaceutical Co. Ltd.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Alimera Sciences
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
10.13. Intas Pharmaceuticals Ltd.
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments